ProKidney Corp. (PROK)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $417.20M
Last updated: Nov 17, 2026 at 4:42 PM ET
ProKidney Corp. (PROK) Statistics
ProKidney (PROK) has a market cap of $417.20M and an enterprise value of $337.99M. It kept -23445.42% of revenue as net income over the last 12 months. Its share count is up 53.90% from a year earlier.
Total Valuation
Enterprise value is 18.99% below the market cap, as cash exceeds debt.
| Market Cap | $417.20M |
|---|---|
| Enterprise Value | $337.99M |
| Latest price (Nov 17, 2026) | $1.10 |
Key Dates
The next earnings report is expected on Mar 16, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 16, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 294.9x.
| P/S Ratio | 294.9x |
|---|---|
| Forward P/S | 562.8x |
Price Statistics
The stock is down 54.36% over 52 weeks and trades 26.17% below its 50-day average.
| Beta (1Y) | 1.77 |
|---|---|
| 52-Week Change | -54.36% |
| 1-Month Change | -21.15% |
| 3-Month Change | -25.68% |
| 6-Month Change | -29.03% |
| Total Return (1Y) | -54.36% |
| Total Return (3Y CAGR) | -3.13% |
| Return vs SPY (1Y) | -63.31% |
| Max Drawdown (1Y) | -59.53% |
| Max Drawdown (3Y) | -87.84% |
| Sharpe Ratio (1Y) | -1.00 |
| Correlation with SPY (1Y) | 0.33 |
| 50-Day Average | $1.49 |
| 200-Day Average | $1.76 |
| 52-Week Range | $0.87 to $2.65 |
| RSI (14 Days) | 38.2 |
| Average Volume (20 Days) | 1.41M |
Financial Position
Current assets cover 5.04x current liabilities.
| Current Ratio | 5.04x |
|---|---|
| Quick Ratio | 5.04x |
| Interest Coverage | -10690.83x |
Returns and Efficiency
Return on invested capital is 21.04% over the last 12 months, against a 5-year average of 16.32%.
| Return on Assets (ROA) | -86.41% |
|---|---|
| Return on Invested Capital (ROIC) | 21.04% |
| ROA (5Y Average) | -55.97% |
| ROIC (5Y Average) | 16.32% |
| Asset Turnover | 0.00x |
Scores
PROK has an Altman Z-Score of -7.22, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -7.22 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $775.00K over the last 12 months is up 4.17% from the 12 months before.
| Revenue | $775.00K |
|---|---|
| Revenue Growth (YoY) | +4.17% |
| Gross Profit | $775.00K |
| Operating Income | -$192.44M |
| Pretax Income | -$183.72M |
| Net Income | -$181.70M |
| Reported EPS (TTM) | -$0.60 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $81.36M |
|---|---|
| Total Debt | $2.14M |
| Net Cash | $79.21M |
| Net Cash Per Share | $0.38 |
| Working Capital | $121.41M |
| Shareholder Equity | -$906.85M |
| Total Assets | $210.28M |
| Total Liabilities | $33.30M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $14.60M of capital spending, operating cash flow left -$167.83M of free cash flow.
| Operating Cash Flow | -$153.22M |
|---|---|
| Capital Expenditures | $14.60M |
| Free Cash Flow | -$167.83M |
| FCF Per Share | -$0.80 |
| Depreciation and Amortization | $6.85M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -24830.32%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -24830.32% |
| Pretax Margin | -23706.19% |
| Net Margin | -23445.42% |
| FCF Margin | -21654.97% |
Dividends and Yields
PROK does not pay a dividend. Its free cash flow yield is -73.44%.
| FCF Yield | -73.44% |
|---|---|
| Buyback Yield | -7.51% |
| Shareholder Yield | -7.51% |
Peer Position
Against 7 similar companies, PROK has the highest P/S.
P/S RatioPeer median 1.7x
ROICPeer median -4.39%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +17.57%
| P/S Ratio | 294.9x vs 1.7x median |
|---|---|
| ROIC | 21.04% vs -4.39% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +4.17% vs +17.57% median |
Analyst Forecast
Consensus estimates put revenue growth at -16.02% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -16.02% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About PROK
What is PROK's market cap?
ProKidney has a market cap of $417.20M. Its enterprise value, which adds debt and subtracts cash, is $337.99M.
How many shares of PROK are outstanding?
ProKidney has 207.76M shares outstanding. The count is up 53.90% from a year earlier.
Does PROK pay a dividend?
No. ProKidney does not pay a dividend.
How much debt does PROK have?
ProKidney has $2.14M of total debt and $81.36M of cash and equivalents, a net cash position of $79.21M.
PROK pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors